Cellceutix CEO, Leo Ehrlich, Conducts Interview With "Biotech Stock Trader"; Dr. Paul Ginsberg, (Renowned Patent Attorney) Joins Cellceutix Advisory Board
BEVERLY, Mass., April 18, 2011 /PRNewswire/ -- Cellceutix Corporation (OTCQB: CTIX, "the Company"), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions including drug-resistant cancers, is pleased to announce that its CEO Leo Ehrlich has conducted an interview with Biotech Stock Trader, a news and information portal for investors in pharmaceutical and biotechnology firms. The interview provides additional insight into Cellceutix, the future path of the Company, and its business model. The company's potential and developments are discussed as well as the Cellceutix pipeline, upcoming clinical trials, and the Company's potential revolutionary cancer medication breakthrough with Kevetrin™ to reactivate p53, the "Guardian Angel of the Human Genome."
The interview is available for viewing on the Cellceutix website at http://www.cellceutix.com/news/BiotechStockTrader.html and at http://biotechstocktrader.com/cellceutix-otcqb-ctix-management-outlines-enormous-potential-in-exclusive-interview-200/.
Cellceutix also is pleased to announce that they have added renowned patent attorney, Dr. Paul Ginsberg, to their Advisory Board.
Cellceutix CEO Leo Ehrlich commented, "We are excited that Dr. Ginsberg wanted to expand his relationship with Cellceutix. Dr. Ginsberg has already been of great help in the patent process of Kevetrin™ and we look forward to his knowledge and experience as we finalize the patent application for our autism drug. Dr. Ginsberg, with his in depth understanding of pharmaceutical chemistry, is a perfect fit to join our other amazing scientific advisors who have been of such enormous help to our early and extraordinary scientific successes. "Commenting on joining the Cellceutix Advisory Board, Dr. Ginsburg stated, "I have been working closely with Cellceutix and Dr. Menon for some time now and based on my past experience in the field, I see great potential in the Company. I am both pleased and excited to join the exceptional Cellceutix team and look forward to what the future may hold with not only Kevetrin™, but KM-391 for autism and other drugs in the pipeline which I have gotten to know quite well."
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV